Healthcare / BiotechnologyNasdaqCM
$5.31
-0.18 (-3.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-61.3M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-125.9%
↓Gross Margin
N/A
•Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+101.6%
FCF CAGR
—
FCF margin
-518.8%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.7M · net income $-33.4M · FCF $-39.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $7.7M | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M | $231000.00 |
| Net Income | $-33.4M | $-33.4M | $-63.1M | $-69.2M | $-88.1M | $-98.6M | $-60.7M |
| EBITDA | $-33.3M | $-33.3M | $-66.5M | $-74.3M | $-88.7M | $-91.6M | $-48.6M |
| EPS | -17.85 | -17.85 | -33.00 | -36.60 | -47.20 | -59.40 | — |
| Operating Margin | -450.1% | -450.1% | -887.3% | -967.4% | -1576.6% | -7364.1% | -21290.9% |
| Net Margin | -433.7% | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% | -26289.2% |
| Balance Sheet | |||||||
| Debt/Equity | 0.87 | 0.87 | 0.44 | 0.18 | 0.13 | — | — |
| Current Ratio | 3.51 | 3.51 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-39.9M | $-39.9M | $-61.3M | $-69.7M | $-78.5M | $-59.4M | $-50.6M |
| Returns | |||||||
| ROE | -125.9% | -125.9% | -110.4% | -61.4% | -51.4% | -39.4% | 57.9% |
| Valuation | |||||||
| P/B | 0.36 | 0.36 | 0.39 | 0.40 | 0.31 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 0.1% | 0.1% | -2.4% | 37.5% | — | 445.5% | — |
| EPS Growth | 45.9% | 45.9% | 9.8% | 22.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-33.00 → -17.85
Residual
-16.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.